INVESTIGADORES
RABINOVICH Gabriel Adrian
congresos y reuniones científicas
Título:
Galectin-1 (Gal-1) is a molecular target of an antimetastatic dose of cyclophosphamide (Cy) in a rat B-cell lymphoma tumor model
Autor/es:
MARIANO ZACARÍAS FLUCK, MARÍA JOSÉ RICO, JUAN M. ILARREGUI, GABREL A. RABINOVICH, O. GRACIELA SCHAROVSKY
Lugar:
Córdoba, Argentina
Reunión:
Congreso; VII Congreso Latinoamericano de Inmunología; 2005
Institución organizadora:
Latin American Society of Immunology
Resumen:
GALECTIN-1 (GAL-1) IS A MOLECULAR TARGET OF AN ANTIMETASTATIC DOSE OF CYCLOPHOSHAMIDE (CY) IN A RAT B-CELL LYMPHOMA TUMOR MODEL   Zacarías MF1,3, Rico MJ1,3, Ilarregui JM2, Rabinovich GA2, Scharovsky OG1   1Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario; 2 Laboratorio de Inmunogenética, Hospital de Clínicas, Universidad de Buenos Aires, Argentina; 3 Contributed  equally   Our aim was to study the involvement of Gal-1 as  molecular target of low-dose Cy antimetastatic treatment of a rat B-cell lymphoma (L-TACB). Inbred e rats were challenged with L-TACB s.c. and treated, on day 14, with 10 mg/kg of body weight. At different time-points primary tumor, spleen and lymph node metastasis of control and treated rats were excised and used for evaluation of Gal-1  and bcl-2 expression by Western-blot. Viability was determined by MTS/PMS colorimetric assay and apoptosis by DNA ladder and Annexin V, for tumor or spleen cells incubated or not with Gal-1. Also, the signaling pathways driving to Gal-1 expression were studied with different inhibitors. We found an increased Gal-1 expression by the primary tumor, which was positively correlated with tumor volume (p=0.01), and a lower expression in spleen and metastatic cells. Cy restored the basal levels of Gal-1 in primary tumor and spleen and led to increased viability and apoptosis inhibition of spleen cells. The reduction of spleen cells apoptosis by Cy cannot be reverted by Gal-1 addition. p38-MAPK and mTOR pathways are involved in L-TACB Gal-1 expression. Gal-1 could be considered a pivotal target of Cy which would be responsible for overcoming the tumor-induced immunosuppression leading to the inhibition of metastatic growth.